nach oben

Archives of Virology

Erschienen in:

01.12.2010 | Brief Report

Comparative reactivity of serum samples from Argentinean HIV-infected patients with V3 peptides from subtype B or BF recombinants

verfasst von: J. Ambrosioni, G. Andreani, C. Acuipil, R. Barral, R. Rabinovich, Liliana Martinez Peralta

Erschienen in: Archives of Virology | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

To analyze humoral cross-reactivity to V3 peptides from subtype B and BF recombinant forms, plasma samples from 50 HIV-1-infected patients were characterized by sequencing fragments of the env and pol genes. An in-house EIA was performed using peptides corresponding to the 15 central amino acids of the V3 loop of gp120 from subtypes B (MN, SF2) and F1 and a consensus peptide from Argentinean BF recombinants. No differences were found with respect to the infecting subtype, but significant differences were found among the peptides. Reactivity was higher against the MN and BF peptides in both groups infected with subtype B (n = 28) and BF (n = 22) recombinants than against subtype F1 and SF2 peptides.

McCutchan FE (2000) Understanding the genetic diversity of HIV-1. AIDS 14(Suppl 3):S31–S44PubMed

Sabino EC, Shpaer EG, Morgado MG, Korber BT, Diaz RS et al (1994) Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil. J Virol 68:6340–6346PubMed

Carr JK, Salminen MO, Koch C, Gotte D, Artenstein AW et al (1996) Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J Virol 70:5935–5943PubMed

Marquina S, Leitner T, Rabinovich RD, Benetucci J, Libonatti O et al (1996) Coexistence of subtypes B, F, and as B/F env recombinant of HIV type 1 in Buenos Aires Argentina. AIDS Res Hum Retroviruses 12:1651–1654CrossRefPubMed

Fernandez-Medina D, Jansson M, Rabinovich RD, Libonatti O, Wigzell H (1999) Identification of human immunodeficiency virus type 1 subtypes B and F B/F recombinant and dual infection with these subtypes in Argentina. Scand J Infect Dis 31:235–242CrossRefPubMed

Comez Carrillo M, Salomon H, Pando MA, Kijak G, Avila MM (2001) Distribution of subtypes and recombinant of HIV. Situation in Argentina. Medicina (B Aires) 61:881–889

Carr JK, Avila M, Gomez Carrillo M, Salomon H, Hierholzer J et al (2001) Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America. AIDS 15:F41–F47CrossRefPubMed

Avila MM, Pando MA, Carrion G, Peralta LM, Salomon H et al (2002) Two HIV-1 epidemics in Argentina: different genetic subtypes associated with different risk groups. J Acquir Immune Defic Syndr 29:422–426PubMed

Gomez Carrillo M, Avila M, Hierholzer J, Pando M, Martinez PL et al (2002) Mother-to-child HIV type 1 transmission in Argentina: BF recombinants have predominated in infected children since the mid-1980s. AIDS Res Hum Retroviruses 18:477–483CrossRefPubMed

10.

Turk G, Gherardi MM, Laufer N, Saracco M, Luzzi R et al (2008) Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants. J Virol 82:2853–2866CrossRefPubMed

11.

Humbert M, Dietrich U (2006) The role of neutralizing antibodies in HIV infection. AIDS Rev 8:51–59PubMed

12.

Zolla-Pazner S (2005) Improving on nature: focusing the immune response on the V3 loop. Hum Antibodies 14:69–72PubMed

13.

Teixeira SL, Bastos FI, Telles PR, Hacker MA, Brigido LF et al (2004) HIV-1 infection among injection and ex-injection drug users from Rio de Janeiro, Brazil: prevalence, estimated incidence and genetic diversity. J Clin Virol 31:221–226CrossRefPubMed

14.

Eyer-Silva WA, Couto-Fernandez JC, Morgado MG (2007) Molecular epidemiology of HIV type 1 in inner Rio De Janeiro State, Brazil. AIDS Res Hum Retroviruses 23:303–308CrossRefPubMed

15.

Buonaguro L, Tagliamonte M, Tornesello M, Buonaguro FM (2007) Evolution of the HIV-1 V3 region in the Italian epidemic. New Microbiol 30:1–11PubMed

16.

Sierra M, Thomson MM, Rios M, Casado G, Castro RO et al (2005) The analysis of near full-length genome sequences of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Chile, Venezuela and Spain reveals their relationship to diverse lineages of recombinant viruses related to CRF12_BF. Infect Genet Evol 5:209–217CrossRefPubMed

17.

Stanfield RL, Gorny MK, Zolla-Pazner S, Wilson IA (2006) Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J Virol 80:6093–6105CrossRefPubMed

18.

Cardozo T, Swetnam J, Pinter A, Krachmarov C, Nadas A et al (2009) Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies. AIDS Res Hum Retroviruses 25:441–450CrossRefPubMed

19.

Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN et al (2005) Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B V3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J Virol 79:780–790CrossRefPubMed

20.

Pampuro SE, Calarota SA, Marquina SA, Rabinovich RD, Libonatti OV (1996) Reactivity of Argentine serum samples against synthetic V3-based HIV-1 peptides. J Acquir Immune Defic Syndr Hum Retrovirol 12:527–528PubMed

21.

Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C et al (2003) Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313:387–400CrossRefPubMed

22.

Teeraputon S, Louisirirojchanakul S, Auewarakul P (2005) N-linked glycosylation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing antibodies. Viral Immunol 18:343–353CrossRefPubMed

23.

Schilling R, Heil A, Langner K, Pohlmeyer K, Larsen M et al (2006) A multivalent HIV-vaccine: development of a plasmid DNA for the expression of HIV envelope glycoproteins with hypervariable V3-loop domains. Vaccine 24:4648–4650CrossRefPubMed

24.

Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC et al (2008) Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 82:7369–7378CrossRefPubMed

25.

Eda Y, Takizawa M, Murakami T, Maeda H, Kimachi K et al (2006) Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J Virol 80:5552–5562CrossRefPubMed

26.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J et al (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220CrossRefPubMed

Titel: Comparative reactivity of serum samples from Argentinean HIV-infected patients with V3 peptides from subtype B or BF recombinants
verfasst von: J. Ambrosioni
G. Andreani
C. Acuipil
R. Barral
R. Rabinovich
Liliana Martinez Peralta
Publikationsdatum: 01.12.2010
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 12/2010
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-010-0785-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Comparative reactivity of serum samples from Argentinean HIV-infected patients with V3 peptides from subtype B or BF recombinants

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2010

Two novel begomoviruses belonging to different lineages infecting Rhynchosia minima

Enhanced cell fusion activity in porcine epidemic diarrhea virus adapted to suckling mice

Isolation of bluetongue virus serotype 1 (BTV-1) from goats and its phylogenetic relationship to other BTV-1 isolates worldwide based on full-length sequence of genome segment-2

In vitro inactivation of feline calicivirus (FCV) by chemical disinfectants: resistance variation among field strains

Generation of representative primary virus isolates from blood plasma after isolation of HIV-1 with CD44 MicroBeads

Kaposi’s sarcoma-associated herpesvirus load in asymptomatic contacts of Cuban epidemic KS patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin